Regeneron Pharmaceuticals Inc and Sanofi said on Friday their experimental treatment for eczema proved highly effective in two large studies, without serious side effects often seen with standard treatments for the chronic inflammatory skin disease. The drugmakers said they would seek U.S. approval this year for their injectable drug, dupilumab, based upon strong results in the trials involving almost 1,400 adults with moderate to severe disease. In the two identical Phase 3 studies, respectively, there was a clearing or near clearing of skin lesions among 37 percent and 36 percent of patients who received dupilumab weekly and 38 percent and 36 percent who received injections every two weeks.
Go here to read the rest:
Regeneron, Sanofi eczema drug clears hurdles in big trials